We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03878719
Recruitment Status : Terminated (The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and not based on safety concerns.)
First Posted : March 18, 2019
Last Update Posted : April 3, 2023
Sponsor:
Collaborator:
Pierre Fabre Laboratories
Information provided by (Responsible Party):
Pfizer

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Terminated
Actual Primary Completion Date : August 19, 2022
Actual Study Completion Date : August 19, 2022